Coagulation factor viii


ReFacto AF 2000 IU powder and solvent for solution forinjection

ReFacto AF contains the active substance moroctocog alfa, human coagulation factor VIII produced by recombinant DNA technology. Factor VIII is necessary for the blood to form clots and stop bleedings. In patients with haemophilia A (inborn factor... Mehr

Producer: Wyeth Europa Ltd

Therapeutic group: Antihemorrhagics


ReFacto AF 1000 IU powder and solvent for solution forinjection

ReFacto AF contains the active substance moroctocog alfa, human coagulation factor VIII produced by recombinant DNA technology. Factor VIII is necessary for the blood to form clots and stop bleedings. In patients with haemophilia A (inborn factor... Mehr

Producer: Wyeth Europa Ltd

Therapeutic group: Antihemorrhagics


ReFacto AF 500 IU powder and solvent for solution forinjection

ReFacto AF contains the active substance moroctocog alfa, human coagulation factor VIII produced by recombinant DNA technology. Factor VIII is necessary for the blood to form clots and stop bleedings. In patients with haemophilia A (inborn factor... Mehr

Producer: Wyeth Europa Ltd

Therapeutic group: Antihemorrhagics


ReFacto AF 250 IU powder and solvent for solution forinjection

ReFacto AF contains the active substance moroctocog alfa, human coagulation factor VIII produced by recombinant DNA technology. Factor VIII is necessary for the blood to form clots and stop bleedings. In patients with haemophilia A (inborn factor... Mehr

Producer: Wyeth Europa Ltd

Therapeutic group: Antihemorrhagics


Helixate NexGen 3000 IU powder and solvent for solution forinjection

Helixate NexGen 3000 IU contains the active substance human recombinant coagulation factor VIII (octocog alfa).Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).This preparation does not contain... Mehr

Producer: Bayer Schering Pharma AG

Therapeutic group: Antihemorrhagics


Helixate NexGen 2000 IU powder and solvent for solution forinjection

Helixate NexGen 2000 IU contains the active substance human recombinant coagulation factor VIII (octocog alfa).Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).This preparation does not contain... Mehr

Producer: Bayer Schering Pharma AG

Therapeutic group: Antihemorrhagics


Helixate NexGen 1000 IU powder and solvent for solution forinjection

Helixate NexGen 1000 IU contains the active substance human recombinant coagulation factor VIII (octocog alfa).Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).This preparation does not contain... Mehr

Producer: Bayer Schering Pharma AG

Therapeutic group: Antihemorrhagics


Helixate NexGen 500 IU powder and solvent for solution forinjection

Helixate NexGen 500 IU contains the active substance human recombinant coagulation factor VIII (octocog alfa).Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).This preparation does not contain... Mehr

Producer: Bayer Schering Pharma AG

Therapeutic group: Antihemorrhagics


Helixate NexGen 250 IU powder and solvent for solution forinjection

Helixate NexGen 250 IU contains the active substance human recombinant coagulation factor VIII (octocog alfa).Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).This preparation does not contain... Mehr

Producer: Bayer Schering Pharma AG

Therapeutic group: Antihemorrhagics


ADVATE 3000 IU powder and solvent for solution forinjection

ADVATE contains the active substance octocog alfa, human coagulation factor VIII produced by recombinant DNA technology. Factor VIII is necessary for the blood to form clots and stop bleedings. In patients with haemophilia A (inborn factor VIII... Mehr

Producer: Baxter AG

Therapeutic group: Antihemorrhagics


ADVATE 2000 IU powder and solvent for solution forinjection

ADVATE contains the active substance octocog alfa, human coagulation factor VIII produced by recombinant DNA technology. Factor VIII is necessary for the blood to form clots and stop bleedings. In patients with haemophilia A (inborn factor VIII... Mehr

Producer: Baxter AG

Therapeutic group: Antihemorrhagics


ADVATE 1500 IU powder and solvent for solution forinjection

ADVATE contains the active substance octocog alfa, human coagulation factor VIII produced by recombinant DNA technology. Factor VIII is necessary for the blood to form clots and stop bleedings. In patients with haemophilia A (inborn factor VIII... Mehr

Producer: Baxter AG

Therapeutic group: Antihemorrhagics


ADVATE 1000 IU powder and solvent for solution forinjection

ADVATE contains the active substance octocog alfa, human coagulation factor VIII produced by recombinant DNA technology. Factor VIII is necessary for the blood to form clots and stop bleedings. In patients with haemophilia A (inborn factor VIII... Mehr

Producer: Baxter AG

Therapeutic group: Antihemorrhagics


ADVATE 500 IU powder and solvent for solution for injection

ADVATE contains the active substance octocog alfa, human coagulation factor VIII produced by recombinant DNA technology. Factor VIII is necessary for the blood to form clots and stop bleedings. In patients with haemophilia A (inborn factor VIII... Mehr

Producer: Baxter AG

Therapeutic group: Antihemorrhagics


ADVATE 250 IU powder and solvent for solution for injection

ADVATE contains the active substance octocog alfa, human coagulation factor VIII produced by recombinant DNA technology. Factor VIII is necessary for the blood to form clots and stop bleedings. In patients with haemophilia A (inborn factor VIII... Mehr

Producer: Baxter AG

Therapeutic group: Antihemorrhagics


Cookies help us deliver our services. By using our services, you agree to our use of cookies. OK